Serum 25-hydroxyvitamin D levels and health outcomes of hospitalization owing to COVID-19: a retrospective cross-sectional study.

IF 1.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Journal of International Medical Research Pub Date : 2024-08-01 DOI:10.1177/03000605241271770

Irina Metonidze, Nestan Bostoganashvili, Tamar Goderidze, David Tananashvili

{"title":"Serum 25-hydroxyvitamin D levels and health outcomes of hospitalization owing to COVID-19: a retrospective cross-sectional study.","authors":"Irina Metonidze, Nestan Bostoganashvili, Tamar Goderidze, David Tananashvili","doi":"10.1177/03000605241271770","DOIUrl":null,"url":null,"abstract":"Objective: We investigated the role of serum 25(OH)D (25-hydroxyvitamin D) in COVID-related health outcomes.Methods: We conducted a retrospective cross-sectional study using data of the National Center of Disease Control and Public Health, Georgia. We extracted patient data including length of hospital stay, transfer to the intensive care unit, requirement for oxygen therapy, treatment with glucocorticoids, and symptoms. After obtaining written informed consent, 384 individuals were enrolled. We divided participants into three groups according to 25(OH)D levels: group 1 = 25(OH)D <12 ng/mL (n = 83), group 2 = 25(OH)D 12-20 ng/mL (n = 141), and group 3 = 25(OH)D >20 ng/mL (n = 160).Results: The odds ratio (OR) for hospitalization in group 1 versus group 2 was 8.7 (95% confidence interval [CI] 3.6-21.3) and 5.6 for group 1 versus 3 (95% CI 2.7-11.9). Regarding oxygen therapy, OR = 28.41 for group 1 versus 2 (95% CI 3.7-220.5) and OR = 5.2 for group 1 versus 3 (95% CI 1.9-14.1). Regarding treatment with glucocorticoids, OR = 3.7 for group 1 versus 2 (95% CI 1.1-12.5) and OR = 8.4 for group 1 versus 3 (95% CI 1.8-40.7).Conclusion: COVID-19-related morbidity was associated with decreased serum 25(OH)D levels. Future studies should investigate the potential role of vitamin D sufficiency in preventing SARS-CoV-2 infection and mortality.","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350547/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605241271770","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We investigated the role of serum 25(OH)D (25-hydroxyvitamin D) in COVID-related health outcomes.

Methods: We conducted a retrospective cross-sectional study using data of the National Center of Disease Control and Public Health, Georgia. We extracted patient data including length of hospital stay, transfer to the intensive care unit, requirement for oxygen therapy, treatment with glucocorticoids, and symptoms. After obtaining written informed consent, 384 individuals were enrolled. We divided participants into three groups according to 25(OH)D levels: group 1 = 25(OH)D <12 ng/mL (n = 83), group 2 = 25(OH)D 12-20 ng/mL (n = 141), and group 3 = 25(OH)D >20 ng/mL (n = 160).

Results: The odds ratio (OR) for hospitalization in group 1 versus group 2 was 8.7 (95% confidence interval [CI] 3.6-21.3) and 5.6 for group 1 versus 3 (95% CI 2.7-11.9). Regarding oxygen therapy, OR = 28.41 for group 1 versus 2 (95% CI 3.7-220.5) and OR = 5.2 for group 1 versus 3 (95% CI 1.9-14.1). Regarding treatment with glucocorticoids, OR = 3.7 for group 1 versus 2 (95% CI 1.1-12.5) and OR = 8.4 for group 1 versus 3 (95% CI 1.8-40.7).

Conclusion: COVID-19-related morbidity was associated with decreased serum 25(OH)D levels. Future studies should investigate the potential role of vitamin D sufficiency in preventing SARS-CoV-2 infection and mortality.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血清 25- 羟维生素 D 水平与 COVID-19 导致的住院健康后果：一项回顾性横断面研究。

目的我们研究了血清 25(OH)D（25-羟基维生素 D）在 COVID 相关健康结果中的作用：我们利用格鲁吉亚国家疾病控制和公共卫生中心的数据进行了一项回顾性横断面研究。我们提取了患者的数据，包括住院时间、转入重症监护室、氧疗需求、糖皮质激素治疗和症状。在获得书面知情同意后，384 人加入了研究。我们根据25（OH）D水平将参与者分为三组：第一组=25（OH）D 20纳克/毫升（n = 160）：结果：第 1 组与第 2 组相比，住院治疗的几率比（OR）为 8.7（95% 置信区间 [CI] 3.6-21.3），第 1 组与第 3 组相比，住院治疗的几率比（OR）为 5.6（95% 置信区间 [CI] 2.7-11.9）。在氧疗方面，1 组与 2 组的 OR = 28.41（95% CI 3.7-220.5），1 组与 3 组的 OR = 5.2（95% CI 1.9-14.1）。在使用糖皮质激素治疗方面，1组与2组的OR=3.7（95% CI 1.1-12.5），1组与3组的OR=8.4（95% CI 1.8-40.7）：结论：COVID-19相关发病率与血清25（OH）D水平下降有关。结论：与 COVID-19 相关的发病率与血清 25（OH）D 水平下降有关。未来的研究应探讨维生素 D 不足在预防 SARS-CoV-2 感染和死亡率方面的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of International Medical Research 医学-药学

CiteScore

3.20

自引率

0.00%

发文量

555

审稿时长

1 months

期刊介绍： _Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis. As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible. Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence. Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements. Print ISSN: 0300-0605